TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects.

摘要: Background/aims Colorectal cancer is one of the most significant health emerging problem in western countries. Patients with colorectal have liver metastases at presentation about 25% cases and another 50% will develop recurrence within next 5 years. Intra-arterial hepatic chemoembolization (TACE) could be a new therapeutic opportunity treatment unresectable or chemorefractory metastases. Methodology Since November 2005 we performed clinical trial TACE irinotecan-eluting beads (DEBIRI) 20 patients affected by from as palliative setting. We developed an intensive intra-arterial lidocaine post-procedure supportive therapy to reduce acute toxic effects Results observed high response rate (80%), reduction lesional contrast enhancement all responding patients. Due treatment, was well tolerated median duration hospitalization 3 days (range 1-10). The important adverse event abdominal pain. Supportive antibiotic antiemetic prophylaxis, intravenous hydratation strictly necessary until stabilization serum levels transaminases prevent infections. Major analgesic morphine must used before procedure. Conclusions Our results suggest that using DEBIRI feasible pretreated CRC adopting adequate side effects.